X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-24-2024-1488.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020563
https://www.reuters.com/world/us/economists-warn-costs-if-us-medicare-covers-new-obesity-drugs-2023-03-11/
https://www.cnbc.com/2023/03/01/lilly-cuts-insulin-prices-70percent-cap-prices-at-35-per-month-for-private-insurance.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761109
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-25-2022-1653460687.pdf
https://www.fiercepharma.com/pharma/as-lilly-gears-up-for-key-2022-launches-its-existing-meds-post-solid-growth
https://endpts.com/eli-lilly-ordered-to-pay-royalties-on-blockbuster-diabetes-drugs-though-exact-damages-are-unclear/
https://www.globenewswire.com/news-release/2021/10/14/2313915/0/en/Adocia-s-partner-Tonghua-Dongbao-Receives-Clearance-to-Start-Ultra-Rapid-Insulin-BioChaperone-Lispro-Phase-3-Trial-to-Treat-Type-1-and-Type-2-Diabetes-in-China.html
https://www.business-standard.com/article/companies/cipla-to-sell-eli-lilly-s-insulin-products-humalog-trulicity-in-india-121100400207_1.html
https://www.fiercepharma.com/pharma/response-to-new-price-pressures-lilly-cuts-cost-generic-insulin-lispro-injecton-by-40
https://www.prnewswire.com/news-releases/fda-approves-lyumjev-insulin-lispro-aabc-injection-100-unitsml-for-use-in-insulin-pumps-301355407.html
https://www.prnewswire.com/news-releases/nuevos-datos-sobre-las-insulinas-aspart-gl-asp-lispro-gl-lis-y-glargina-gl-gla--802413956.html
https://www.prnewswire.com/news-releases/new-data-on-phase-1-proposed-biosimilar-gan--lee-insulins-aspart-gl-asp-lispro-gl-lis-and-glargine-gl-gla-presented-at-the-american-diabetes-associations-81st-scientific-sessions-301324495.html
https://www.prnewswire.com/news-releases/lilly-and-dexcom-team-up-on-new-program-to-help-improve-diabetes-management-301147221.html
https://www.fiercebiotech.com/research/ultrafast-insulin-by-stanford-team-cuts-peak-time-to-minutes-pigs
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761109
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lyumjevtm-insulin-lispro-aabc-injection-lillys-new
https://investor.lilly.com/news-releases/news-release-details/lower-priced-versions-humalogr-mix7525tm-kwikpenr-and-humalogr
http://www.pharmatimes.com/news/givlaari,_nubeqa_among_jan_chmp_decisions_1323999
https://www.washingtonpost.com/business/economy/under-fire-over-high-prices-eli-lilly-promised-cheaper-insulin-in-2019-the-result-has-some-senators-steamed/2019/12/26/6c440b44-204e-11ea-86f3-3b5019d451db_story.html
https://endpts.com/eli-lilly-spotlights-early-oncology-in-first-pipeline-review-since-rd-shift/
https://www.fiercepharma.com/pharma/senators-say-lilly-s-discounted-insulin-program-has-failed-patients-but-ceo-ricks-calls
https://www.biospace.com/article/judge-dismisses-white-coat-whistleblower-allegations-against-bayer-eli-lilly/?s=95
https://www.biospace.com/article/judge-dismisses-white-coat-whistleblower-allegations-against-bayer-eli-lilly/
https://www.thepharmaletter.com/article/eli-lilly-to-face-competition-in-russian-insulin-lispro-market
https://www.prnewswire.com/news-releases/lillys-ultra-rapid-lispro-provided-similar-a1c-reductions-compared-to-humalog-insulin-lispro-with-superior-post-meal-blood-glucose-reductions-300864210.html
https://endpts.com/fda-sends-novavax-back-to-the-clinic-stoke-therapeutics-sets-terms-for-upsized-101m-ipo/
https://www.pharmaceutical-technology.com/news/lilly-half-price-humalog-insulin/
https://www.fiercepharma.com/pharma/eli-lilly-launches-50-cheaper-humalog-generic-as-debate-over-rising-insulin-prices-drags
https://www.cnbc.com/2019/03/25/eli-lilly-discloses-pricing-data-for-its-popular-insulin-humalog.html
https://www.nytimes.com/2019/03/21/opinion/diabetes-insulin-generics-humalog.html
https://www.fiercepharma.com/pharma/now-lilly-has-a-cheaper-generic-humalog-will-novo-nordisk-and-sanofi-follow
https://www.fiercepharma.com/pharma/lilly-offers-generic-humalog-at-half-price-amid-bipartisan-pressure-rising-insulin-costs
https://www.reuters.com/article/us-novartis-insulin/novartis-chinas-gan-lee-push-into-insulin-amid-diabetes-epidemic-idUSKBN1OI1DE?feedType=RSS&feedName=healthNews
https://uk.reuters.com/article/us-lilly-study/eli-lillys-diabetes-drug-shows-promise-in-mid-stage-trial-idUKKCN1ME11Z
https://www.reuters.com/article/us-lilly-study/eli-lillys-diabetes-treatment-meets-main-goal-in-two-late-stage-studies-idUSKCN1MC18E
https://www.xconomy.com/indiana/2018/09/27/eli-lilly-strikes-deal-for-diabetes-pill-to-gain-on-novo-nordisk/
https://www.prnewswire.com/news-releases/lilly-diabetes-solution-center-now-open-to-help-people-with-insulin-affordability-300689746.html
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-July-18-2018-1531894333.pdf
https://www.prnewswire.com/news-releases/new-sanofi-insulin-savings-program-aims-to-lower-out-of-pocket-costs-for-people-living-with-diabetes-300624743.html
https://www.fiercepharma.com/regulatory/sanofi-wins-approval-for-humalog-copycat-admelog-as-fda-pushes-more-competition
https://www.reuters.com/article/sanofi-fr-fda/fda-clears-sanofis-follow-on-diabetes-biologic-of-lillys-humalog-idUSL3N1OB4H4?rpc=401&
https://www.pharmacompass.com/pdf/news/sanofi-aventis-insulin-lispro-sanofi-receives-approval-in-europe-1506163399.pdf
http://www.fiercepharma.com/pharma/sanofi-wins-tentative-fda-approval-for-humalog-biosim-putting-billions-lilly-sales-at-risk
http://raps.org/Regulatory-Focus/News/2017/09/05/28402/The-505b2-Pathway-and-Why-Some-Follow-on-Insulins-Aren%E2%80%99t-Yet-Biosimilars-in-the-US/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails
Market Place
Share 
